Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - For the period from January to September 2025, Angli康 reported a revenue of 1.055 billion yuan, a year-on-year decrease of 5.92%. However, the net profit attributable to shareholders increased by 55.59% to 77.6899 million yuan [2]. - The company has distributed a total of 360 million yuan in dividends since its A-share listing, with 128 million yuan distributed over the past three years [3]. Stock Performance - As of November 26, Angli康's stock price increased by 2.04% to 40.60 yuan per share, with a total market capitalization of 8.19 billion yuan. The stock has risen by 213.25% year-to-date, although it has seen a decline of 0.55% over the last five trading days [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) 15 times this year, with the most recent appearance on October 21, where it recorded a net buy of 15.2289 million yuan [1]. Shareholder Structure - As of September 30, 2025, Angli康 had 28,500 shareholders, an increase of 54.58% from the previous period. The average number of circulating shares per shareholder decreased by 35.31% to 6,493 shares [2]. - Notable institutional shareholders include 广发医疗保健股票A, 中欧医疗健康混合A, and several new entrants such as 汇添富创新医药混合A and 长城医药产业精选混合发起式A [3]. Industry Classification - Angli康 operates within the pharmaceutical and biotechnology sector, specifically in the chemical pharmaceutical and chemical formulation sub-industry. The company is associated with various concepts, including ursodeoxycholic acid, Helicobacter pylori, pet economy, hypertension prevention, and vitamins [2].

Core Viewpoint - Qianhong Biopharma's stock price has experienced fluctuations, with a year-to-date increase of 44.17%, but a recent decline in the last five trading days by 4.57% [1] Group 1: Company Overview - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province [2] - The company specializes in the research, production, and sales of various pharmaceutical products, including freeze-dried powders, injections, tablets, and raw materials [2] - The main revenue composition is 62.97% from formulations and 36.70% from raw materials [2] Group 2: Financial Performance - For the period from January to September 2025, Qianhong Biopharma achieved a revenue of 1.215 billion yuan, reflecting a year-on-year growth of 0.61%, and a net profit of 383 million yuan, up 23.79% year-on-year [2] - Cumulatively, the company has distributed 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the last three years [3] Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased to 73,600, with an average of 12,785 circulating shares per person, a decrease of 1.15% from the previous period [2] - The stock has appeared on the "Dragon and Tiger List" seven times this year, with the most recent instance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]

Core Viewpoint - Haisun Pharmaceutical's stock has experienced significant growth this year, with a year-to-date increase of 237.69%, and recent trading activity shows continued interest from institutional investors [2][3]. Group 1: Stock Performance - As of November 18, Haisun Pharmaceutical's stock price was 67.74 CNY per share, with a market capitalization of 8.129 billion CNY [1]. - The stock has seen a rise of 18.68% over the past five trading days, 19.34% over the past 20 days, and 14.81% over the past 60 days [2]. - The company has appeared on the "Dragon and Tiger List" eight times this year, with the most recent net buy of 62.603 million CNY on November 14 [2]. Group 2: Financial Performance - For the period from January to September 2025, Haisun Pharmaceutical reported revenue of 472 million CNY, reflecting a year-on-year growth of 30.80%, and a net profit attributable to shareholders of 32.6785 million CNY, up 16.22% year-on-year [3]. - Cumulative cash dividends since the company's A-share listing amount to 161 million CNY, with 18 million CNY distributed over the past three years [4]. Group 3: Shareholder Structure - As of November 10, the number of shareholders for Haisun Pharmaceutical was 22,100, a decrease of 2.84% from the previous period, with an average of 3,709 circulating shares per shareholder, an increase of 2.93% [3]. - New institutional shareholders include several funds, such as China Europe Enjoy Life Mixed A and Huashan Pharmaceutical Biological Stock Initiation A, indicating growing institutional interest [4]. Group 4: Business Overview - Haisun Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, specializes in the research, production, and sales of chemical preparations, raw materials, and intermediates [2]. - The company's main revenue sources include cardiovascular drugs (87.12%), antibiotics (5.69%), and other therapeutic categories [2].

Core Viewpoint - JiuDian Pharmaceutical's stock has experienced a decline of 4.99% year-to-date, with a recent drop of 2.05% on November 17, 2023, indicating potential challenges in market performance [1]. Financial Performance - For the period from January to September 2025, JiuDian Pharmaceutical reported a revenue of 2.268 billion yuan, representing a year-on-year growth of 5.69%. However, the net profit attributable to shareholders decreased by 9.64% to 406 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 450 million yuan, with 346 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 10.37% to 34,700, while the average number of circulating shares per person increased by 11.56% to 10,645 shares [2]. - The stock's trading activity on November 17 showed a net outflow of 15.41 million yuan from major funds, with significant selling pressure observed [1]. Company Overview - JiuDian Pharmaceutical, established on January 19, 2001, and listed on October 10, 2017, is primarily engaged in the research, production, and sales of pharmaceutical products. The revenue composition includes 82.47% from drug formulations, 7.65% from active pharmaceutical ingredients, and 6.03% from pharmaceutical excipients [1].

11月14日，九典制药盘中上涨2.06%，截至10:45，报17.30元/股，成交1.27亿元，换手率2.01%，总市值 86.54亿元。 资金流向方面，主力资金净流入776.50万元，特大单买入354.53万元，占比2.79%，卖出130.42万元，占 比1.03%；大单买入2502.27万元，占比19.68%，卖出1949.88万元，占比15.34%。 九典制药今年以来股价跌1.93%，近5个交易日涨4.85%，近20日涨2.85%，近60日跌0.35%。 资料显示，湖南九典制药股份有限公司位于湖南省长沙高新开发区麓天路28号金瑞麓谷科技园A1栋， 成立日期2001年1月19日，上市日期2017年10月10日，公司主营业务涉及医药产品的研发、生产和销 售。主营业务收入构成为：药品制剂82.47%，原料药7.65%，药用辅料6.03%，提取物及其他3.16%，技 术转让及服务0.63%，其他(补充)0.05%。 九典制药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：熊去氧胆酸、中药、创 新药、医药电商、原料药等。 截至9月30日，九典制药股东户数3.47万，较上期减少10.37%；人均流通 ...

Group 1 - The core viewpoint of the news is that Saiseng Pharmaceutical has shown significant stock performance with a year-to-date increase of 79.17%, despite a recent decline over the past 60 days [1] - As of November 12, Saiseng Pharmaceutical's stock price reached 12.56 CNY per share, with a total market capitalization of 6.05 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 15.82 million CNY, indicating positive investor sentiment [1] Group 2 - Saiseng Pharmaceutical's main business revenue composition includes cardiovascular drugs (43.08%), immune system drugs (30.28%), and neurological system drugs (25.17%) [1] - For the period from January to September 2025, the company reported a revenue of 309 million CNY, a year-on-year decrease of 4.41%, while the net profit attributable to the parent company was 51.86 million CNY, reflecting a year-on-year increase of 152.81% [2] - The company has distributed a total of 413 million CNY in dividends since its A-share listing, with 52.02 million CNY distributed in the last three years [3]

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. was established on December 30, 2001, and listed on October 23, 2018. The company is engaged in the research, production, and sales of chemical raw materials and preparations [1] - The main business revenue composition includes preparations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1] Stock Performance - As of November 12, Anglikang's stock price increased by 2.02%, reaching 43.50 CNY per share, with a total market capitalization of 8.775 billion CNY [1] - Year-to-date, Anglikang's stock price has risen by 233.13%, with an 8.42% increase over the last five trading days and a 5.58% increase over the last 20 days, while it has decreased by 17.97% over the last 60 days [1] Financial Performance - For the period from January to September 2025, Anglikang reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while the net profit attributable to shareholders was 77.6899 million CNY, reflecting a year-on-year increase of 55.59% [2] - The company has distributed a total of 341 million CNY in dividends since its A-share listing, with 108 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Anglikang had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which holds 3.3384 million shares, and several new entrants among the top ten circulating shareholders [3]

Core Insights - The stock price of Anglikon increased by 2.07% on November 11, reaching 42.33 CNY per share, with a total market capitalization of 8.539 billion CNY [1] - Year-to-date, Anglikon’s stock has risen by 224.17%, with a recent 3.67% increase over the last five trading days [1] - For the first nine months of 2025, Anglikon reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while net profit attributable to shareholders increased by 55.59% to 77.6899 million CNY [2] Financial Performance - Anglikon has been listed on the stock market since October 23, 2018, and has a primary business focus on the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon includes 43.46% from formulations, 39.82% from raw materials, 12.44% from specialty intermediates, 3.72% from others, and 0.56% from pharmaceutical excipients [1] - Cumulative cash dividends since the A-share listing amount to 341 million CNY, with 108 million CNY distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, Anglikon had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which increased its holdings by 95,050 shares, and new entrants such as Huatai-PineBridge Innovation Medical Mixed A [3]

Core Viewpoint - Xinhua Pharmaceutical's stock has shown a modest increase in recent trading sessions, with a year-to-date rise of 5.05%, despite a decline over the past 60 days [1][2]. Group 1: Stock Performance - On November 7, Xinhua Pharmaceutical's stock rose by 2.33%, reaching 16.24 CNY per share, with a trading volume of 1.20 billion CNY and a turnover rate of 1.52% [1]. - The stock has experienced a net inflow of 620.05 thousand CNY from major funds, with significant buying activity from large orders [1]. - Year-to-date, the stock has appeared on the "Dragon and Tiger List" once, with a net purchase of 15.67 million CNY on January 6 [1]. Group 2: Financial Performance - For the period from January to September 2025, Xinhua Pharmaceutical reported a revenue of 6.763 billion CNY, reflecting a year-on-year growth of 0.42%, while the net profit attributable to shareholders decreased by 25.53% to 256 million CNY [2]. - Cumulative cash dividends since the A-share listing amount to 1.17 billion CNY, with 495 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.60% to 70,700, with an average of 0 circulating shares per person [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several ETFs, all of which have seen a reduction in their holdings compared to the previous period [3].

Core Viewpoint - Guangshentang's stock price has shown significant volatility, with a year-to-date increase of 231.65%, but recent performance indicates a slight decline in the short term [1][2]. Group 1: Stock Performance - As of November 6, Guangshentang's stock price rose by 2.02% to 108.35 CNY per share, with a trading volume of 6.42 billion CNY and a turnover rate of 4.41%, resulting in a total market capitalization of 17.257 billion CNY [1]. - The stock has experienced a 1.40% decline over the last five trading days, a 14.05% increase over the last 20 days, and a 6.15% decline over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on July 31 [1]. Group 2: Financial Performance - For the period from January to September 2025, Guangshentang reported a revenue of 316 million CNY, reflecting a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of -112 million CNY, a decline of 57.96% year-on-year [2]. - The company has cumulatively distributed dividends of 84.6485 million CNY since its A-share listing, with no dividends paid in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Guangshentang increased to 45,800, a rise of 125.95%, while the average number of tradable shares per shareholder decreased by 55.74% to 2,985 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest with 1.7463 million shares, marking its entry as a new shareholder [3].